ASP Isotopes Inc. Form 10-K Summary
Business context and reporting period
ASP Isotopes Inc. filed its Form 10-K for the year ended December 31, 2022. The company is a pre-commercial advanced materials business developing its licensed Aerodynamic Separation Process technology to enrich isotopes. Initial target products are Carbon-14, Molybdenum-100 and Silicon-28, with longer-term plans for Uranium-235 and other isotopes. The company has not generated revenue or produced commercial quantities of isotopes.
The company completed its initial public offering in November 2022, issuing 1.25 million shares at $4.00 per share. Its common stock trades under the symbol ASPI. The filing is an annual report, not a standalone fourth-quarter report.
Financial metrics
| Metric | Year ended December 31, 2022 | Comparable period |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1.27 million | $0.04 million in 2021 inception period |
| General and administrative expense | $3.83 million | $2.57 million |
| Total operating expenses | $5.10 million | $2.61 million |
| Net loss | $4.95 million | $2.61 million |
| Net loss per share, basic and diluted | $0.18 loss | $0.16 loss |
| Cash flow from operations | $(2.94) million | $(0.58) million |
| Cash flow from investing activities | $(4.47) million | $(2.99) million |
| Cash flow from financing activities | $6.64 million | $6.50 million |
| Cash at year-end | $2.39 million | $2.95 million |
| Total assets | $12.50 million | $7.14 million |
| Total liabilities | $2.68 million | $1.14 million |
| Debt | $33,854 of notes payable; no bank debt | $46,900 of notes payable |
Operating margins and gross margins are not meaningful because the company had no revenue. Property and equipment increased to $8.20 million, consisting entirely of construction in progress. The company reported an accumulated deficit of $7.55 million at year-end.
Material changes versus the prior comparable period
- Net loss increased to $4.95 million from $2.61 million, while total operating expenses increased to $5.10 million from $2.61 million.
- Research and development expense increased substantially, primarily reflecting personnel costs, license fees and development activity.
- General and administrative expense increased, including $1.80 million of stock-based compensation and $1.01 million of professional and legal fees.
- Operating cash burn increased to $2.94 million, and investing cash use increased to $4.47 million as construction activity accelerated.
- Cash declined by approximately $0.77 million during 2022 despite $6.64 million of financing cash inflows.
- Construction in progress increased from $2.99 million to $8.20 million, reflecting development of the South African enrichment facilities.
- Common shares outstanding increased from 20.65 million to 35.91 million, reflecting private issuances, warrant settlement, restricted stock and the IPO.
Guidance, outlook, commentary, risks and unusual items
- The company completed construction of its first company-owned light-isotope plant in Pretoria during the first quarter of 2023 and expects a second, larger plant to be completed later in 2023. The filing states that commercial C-14 enrichment is targeted for 2024, subject to feedstock and other conditions.
- A 25-year Mo-100 supply agreement with BRICEM has a stated potential value of up to $27.0 million per year, but the company remains pre-commercial and has not demonstrated commercial-scale Mo-100 production.
- The company entered memoranda of understanding for C-14 tolling arrangements, but timing, quantities and supply dates remain subject to future agreements.
- Klydon failed to complete its turnkey-contract obligations by December 31, 2022. Klydon acknowledged potential damages of $6.05 million and pledged assets as security. The company planned to perfect its interests in those assets, but stated that recovery was uncertain and did not record a receivable.
- The company reported substantial doubt about its ability to continue as a going concern. Cash at December 31, 2022, together with the March 2023 financing, is not expected to fund operations and capital requirements for more than 12 months from issuance of the financial statements.
- In March 2023, the company raised approximately $5.0 million gross, or approximately $4.5 million net, through the issuance of 3.16 million shares and warrants for 3.16 million shares. The financing is dilutive and included placement-agent warrants.
- The company incurred a $100,000 penalty because it did not timely file the resale registration statement required under the March 2023 financing.
- An October 2022 letter from Norsk Medisinsk Syklotronsenter asserted that the company’s Mo-100 license may conflict with a prior Radfarma sublicense. Management believes its licenses are valid and intends to defend its rights. An adverse outcome could impair or eliminate the company’s ability to pursue Mo-100.
- The independent auditor included a going-concern explanatory paragraph. Management also identified material weaknesses in finance and accounting staffing, as well as information-technology logical security and privileged access. Disclosure controls were deemed ineffective at December 31, 2022.
- The company relies heavily on Klydon for licensed technology, plant development and technical expertise. The ASP technology has not yet been demonstrated for commercial production of Mo-100 or U-235.
- Key risks include additional financing needs, construction and commissioning delays, regulatory and export-control requirements, South African power reliability, limited suppliers, intellectual-property disputes, lack of patents, customer concentration, competition and future dilution.
Most important facts for investors to verify
- Whether the first Pretoria facility has been fully commissioned and has produced saleable commercial quantities of C-14.
- Whether the second plant was completed on schedule and whether ASP technology can enrich Mo-100 and Si-28 at the claimed scale.
- The enforceability and commercial status of the BRICEM Mo-100 agreement and the C-14 memoranda of understanding.
- The status and recoverability of the $6.05 million Klydon damage claim and pledged assets.
- Available liquidity after the March 2023 financing, expected monthly cash burn and the timing and terms of additional capital raises.
- The potential impact of the NMS/Radfarma license dispute on Mo-100 commercialization.
- Progress in remediating the identified internal-control material weaknesses.
- Required South African, U.S. and international regulatory approvals, permits and export authorizations, particularly for uranium enrichment and medical applications.
- Fully diluted share count, including outstanding options, warrants, restricted shares and the March 2023 financing securities.